Correspondence on Proton versus Photon Therapy for Oropharyngeal Cancer

This correspondence, published in The Lancet, addresses a recent multi-institutional study led by Steven J. Frank and colleagues regarding the comparison of photon and proton therapies for treating oropharyngeal squamous cell carcinoma. While the author congratulates the team on successfully completing the study, they emphasize that significant questions remain unresolved. A primary focus of the discussion is the difference in side effects between intensity-modulated radiation therapy (IMRT), which uses photons, and intensity-modulated proton therapy (IMPT). Specifically, the text highlights the risk of grade 3 xerostomia, a severe form of dry mouth. According to the Common Toxicity Criteria for Adverse Events (CTCAE), this condition is defined by an inability to eat orally, the need for tube feeding or total parenteral nutrition, or an unstimulated salivary flow rate of less than 0.1 mL/min. The correspondence serves as a critical academic commentary, urging further investigation into the clinical implications and toxicity profiles of these competing radiation treatment modalities for head and neck cancer patients.